FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1893775161> ?p ?o ?g. }

• W1893775161 endingPage "303" @default.
• W1893775161 startingPage "295" @default.
• W1893775161 abstract "Aims To identify the cytochrome P450 (CYP) and UDP‐glucuronosyltransferase (UGT) isoforms responsible for the formation of the primary metabolite(s) of zaltoprofen, and to predict possible drug interactions by investigating the inhibition of CYP isoforms in vitro . Methods The metabolism of zaltoprofen was studied in vitro using recombinant CYP and UGT isoform cDNA‐expression systems. The effects of selective isoform inhibitors on zaltoprofen metabolism were studied using human liver microsomes. The inhibitory effects of zaltoprofen on the metabolism of selective probe substrates for CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 were also determined in human liver microsomes. Results Zaltoprofen was extensively metabolized by CYP2C9 and UGT2B7. CYP2C9 catalysed sulphoxidation but not hydroxylation of zaltoprofen. In the human liver microsomal metabolism study, zaltoprofen metabolism was markedly inhibited by sulphaphenazole, a selective inhibitor of CYP2C9. In the drug interaction study, negligible inhibition (< 15%) of the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 was apparent at 5 µg ml −1 , the maximum plasma concentration observed in humans after oral administration of an 80 mg zaltoprofen tablet. However, zaltoprofen inhibited CYP2C9 by 26% at 5 µg ml −1 . At higher concentrations, zaltoprofen produced some inhibition of CYP2C9 (I C 50 = 19.2 µg ml −1 ; 64.4 µ m ) and CYP3A4 (I C 50 = 53.9 µg ml −1 ; 181 µ m ). The free drug concentrations in plasma (0.02 µg ml −1 , 67.0 n m ) at the C max of the clinically effective doses are much lower than the I C 50 values corrected for the nonspecific binding ratio of zaltoprofen to microsomal protein (15.5 µg ml −1 for CYP3A4, 49.5 µg ml −1 for CYP3A4). Furthermore, the maximum free drug concentrations in the hepatic intracellular was calculated to be 0.068 µg ml −1 and the increase in the AUC in the presence of zaltoprofen was estimated to be only 0.4% for CYP2C9 substrates and 0.1% for CYP3A4 substrates, respectively. Conclusions Zaltoprofen is predominantly metabolized by CYP2C9 and UGT2B7, and is considered unlikely to cause significant drug interactions in vivo when coadministered with CYP substrates at clinically effective doses." @default.
• W1893775161 created "2016-06-24" @default.
• W1893775161 creator A5014214164 @default.
• W1893775161 creator A5049601963 @default.
• W1893775161 creator A5050837826 @default.
• W1893775161 creator A5053792697 @default.
• W1893775161 creator A5063059732 @default.
• W1893775161 creator A5067071843 @default.
• W1893775161 creator A5067937069 @default.
• W1893775161 creator A5070962853 @default.
• W1893775161 creator A5073143341 @default.
• W1893775161 creator A5083330732 @default.
• W1893775161 date "2002-09-01" @default.
• W1893775161 modified "2023-10-18" @default.
• W1893775161 title "Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential" @default.
• W1893775161 cites W1492127548 @default.
• W1893775161 cites W1566607634 @default.
• W1893775161 cites W1576888146 @default.
• W1893775161 cites W1703321169 @default.
• W1893775161 cites W1765706822 @default.
• W1893775161 cites W1855372530 @default.
• W1893775161 cites W1969215912 @default.
• W1893775161 cites W1987941468 @default.
• W1893775161 cites W1997591997 @default.
• W1893775161 cites W200535837 @default.
• W1893775161 cites W2031011202 @default.
• W1893775161 cites W2044695596 @default.
• W1893775161 cites W2058351187 @default.
• W1893775161 cites W2097289594 @default.
• W1893775161 cites W2120700977 @default.
• W1893775161 cites W2122221348 @default.
• W1893775161 cites W2131020156 @default.
• W1893775161 cites W2131614625 @default.
• W1893775161 cites W2144465276 @default.
• W1893775161 cites W2149319043 @default.
• W1893775161 cites W2163879184 @default.
• W1893775161 cites W2166995642 @default.
• W1893775161 cites W2272686432 @default.
• W1893775161 cites W2329706006 @default.
• W1893775161 cites W2339571923 @default.
• W1893775161 cites W2107296820 @default.
• W1893775161 doi "https://doi.org/10.1046/j.1365-2125.2002.01649.x" @default.
• W1893775161 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1874418" @default.
• W1893775161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12236850" @default.
• W1893775161 hasPublicationYear "2002" @default.
• W1893775161 type Work @default.
• W1893775161 sameAs 1893775161 @default.
• W1893775161 citedByCount "20" @default.
• W1893775161 countsByYear W18937751612012 @default.
• W1893775161 countsByYear W18937751612013 @default.
• W1893775161 countsByYear W18937751612015 @default.
• W1893775161 countsByYear W18937751612016 @default.
• W1893775161 countsByYear W18937751612020 @default.
• W1893775161 countsByYear W18937751612022 @default.
• W1893775161 countsByYear W18937751612023 @default.
• W1893775161 crossrefType "journal-article" @default.
• W1893775161 hasAuthorship W1893775161A5014214164 @default.
• W1893775161 hasAuthorship W1893775161A5049601963 @default.
• W1893775161 hasAuthorship W1893775161A5050837826 @default.
• W1893775161 hasAuthorship W1893775161A5053792697 @default.
• W1893775161 hasAuthorship W1893775161A5063059732 @default.
• W1893775161 hasAuthorship W1893775161A5067071843 @default.
• W1893775161 hasAuthorship W1893775161A5067937069 @default.
• W1893775161 hasAuthorship W1893775161A5070962853 @default.
• W1893775161 hasAuthorship W1893775161A5073143341 @default.
• W1893775161 hasAuthorship W1893775161A5083330732 @default.
• W1893775161 hasBestOaLocation W18937751612 @default.
• W1893775161 hasConcept C109650736 @default.
• W1893775161 hasConcept C119795356 @default.
• W1893775161 hasConcept C140027455 @default.
• W1893775161 hasConcept C181199279 @default.
• W1893775161 hasConcept C185592680 @default.
• W1893775161 hasConcept C202751555 @default.
• W1893775161 hasConcept C2777469378 @default.
• W1893775161 hasConcept C2777477808 @default.
• W1893775161 hasConcept C2779907587 @default.
• W1893775161 hasConcept C2781109383 @default.
• W1893775161 hasConcept C33664856 @default.
• W1893775161 hasConcept C3946865 @default.
• W1893775161 hasConcept C50605568 @default.
• W1893775161 hasConcept C526171541 @default.
• W1893775161 hasConcept C55493867 @default.
• W1893775161 hasConcept C62231903 @default.
• W1893775161 hasConcept C86745063 @default.
• W1893775161 hasConcept C86803240 @default.
• W1893775161 hasConcept C87644729 @default.
• W1893775161 hasConcept C89311334 @default.
• W1893775161 hasConcept C98274493 @default.
• W1893775161 hasConceptScore W1893775161C109650736 @default.
• W1893775161 hasConceptScore W1893775161C119795356 @default.
• W1893775161 hasConceptScore W1893775161C140027455 @default.
• W1893775161 hasConceptScore W1893775161C181199279 @default.
• W1893775161 hasConceptScore W1893775161C185592680 @default.
• W1893775161 hasConceptScore W1893775161C202751555 @default.
• W1893775161 hasConceptScore W1893775161C2777469378 @default.
• W1893775161 hasConceptScore W1893775161C2777477808 @default.
• W1893775161 hasConceptScore W1893775161C2779907587 @default.
• W1893775161 hasConceptScore W1893775161C2781109383 @default.

• next